XTX101 Monotherapy and XTX101 & Atezolizumab Combination Therapy in Advanced Solid Tumors - Clinical Trial

¿Cuál es el Propósito de este estudio?

We are doing this study to find out if an experimental drug called XTX101 (the study drug) is a safe and effective option for people who have advanced tumors or metastatic microsatellite stable colorectal cancer. We want to see how well it works on its own and in combination with a drug called atezolizumab.

¿Cuál es la Condición que se está estudiando?

Advanced Solid Tumors or Metastatic Microsatellite Stable Colorectal Cancer

¿Quién puede participar en el Estudio?

Adults ages 18+ who have one of the following forms of cancer:

Advanced solid tumors; OR
Metastic microsatellite stable colorectal cancer

For more information about who can join this study, please contact the study team at gi-oncology-cru@dm.duke.edu or 919-668-1861.

Grupo etario

Adultos

¿Qué Implica?

Si elige unirse a este estudio, podrá:

Get a random assignment (like a coin flip) to either take the study drug on its own or in combination with atezolizumab
Hacerse una biopsia del tumor, si es necesario
Realizar extracciones de sangre
Hacerse estudios de imágenes (tomografía computarizada o resonancia magnética)

Detalles del Estudio

Título Completo

A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of Vilastobart (XTX101) Monotherapy and Vilastobart (XTX101) and Atezolizumab Combination Therapy in Patients with Advanced Solid Tumors

Investigador Principal